Project Details
Description
A Phase 1b Dose Escalation Study of Abemaciclib in Combination with Temozolomide and Irinotecan (Part A) and Abemaciclib in Combination with Temozolomide (Part B) in Pediatric and Young Adult Patients with Relapsed/Refractory Solid Tumors
| Status | Active |
|---|---|
| Effective start/end date | 5/1/21 → 4/30/26 |
Funding
- Eli Lilly G.m.b.H.
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.